NASDAQ:TNXP

Tonix Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy TNXP

*Your capital is at risk

$11.40

-0.320 (-2.73%)

At Close: Jun 03, 2026

Tonix Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 1.85M and sold 18.8K TNXP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	1.85M shares
● Sell	18.8K shares
80% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Feb 25, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (80% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 12, 2026 Buy	Stock Option A-Award	Stillwell Richard Newcomb Director	Director	22 700 Value: $301.5K
May 12, 2026 Buy	Stock Option A-Award	Olukotun Adeoye Y Director	Director	22 700 Value: $301.5K
May 12, 2026 Buy	Stock Option A-Award	Bell Margaret Smith Director	Director	22 700 Value: $301.5K
May 12, 2026 Buy	Stock Option A-Award	Hunter James Randolph Jr Director	Director	22 700 Value: $301.5K
May 12, 2026 Buy	Stock Option A-Award	Treco James Director	Director	22 700 Value: $301.5K
May 12, 2026 Buy	Stock Option A-Award	Grange David L Director	Director	22 700 Value: $301.5K
May 12, 2026 Buy	Stock Option A-Award	Bagger Richard H Director	Director	22 700 Value: $301.5K
May 12, 2026 Buy	Stock Option A-Award	Taylor Carolyn E. Director	Director	22 700 Value: $301.5K
Mar 31, 2026 Buy	Common Stock, $0.001 par value P-Purchase	Lederman Seth Chief Executive Officer	CEO / President	5 000 Value: $63.1K
Mar 18, 2026 Buy	Common Stock, $0.001 par value P-Purchase	Lederman Seth Chief Executive Officer	CEO / President	15 000 Value: $223.4K
Feb 24, 2026 Buy	Stock Option A-Award	Lederman Seth Chief Executive Officer	CEO / President	134 503 Value: $2.40M
Feb 24, 2026 Buy	Stock Option A-Award	Lederman Seth Chief Executive Officer	CEO / President	134 504 Value: $1.92M
Feb 24, 2026 Buy	Stock Option A-Award	Fogarty Siobhan Chief Technology Officer	Officer	39 011 Value: $696.8K
Feb 24, 2026 Buy	Stock Option A-Award	Fogarty Siobhan Chief Technology Officer	Officer	39 012 Value: $557.5K
Feb 24, 2026 Buy	Stock Option A-Award	Sullivan Gregory M Chief Medical Officer	Officer	39 011 Value: $696.8K
Feb 24, 2026 Buy	Stock Option A-Award	Morris Jessica Edgar Chief Operating Officer	C-Suite Officer	39 012 Value: $557.5K
Feb 24, 2026 Buy	Stock Option A-Award	Morris Jessica Edgar Chief Operating Officer	C-Suite Officer	39 011 Value: $696.8K
Feb 24, 2026 Buy	Stock Option A-Award	Saenger Bradley Chief Financial Officer	C-Suite Officer	39 012 Value: $557.5K
Feb 24, 2026 Buy	Stock Option A-Award	Saenger Bradley Chief Financial Officer	C-Suite Officer	39 011 Value: $696.8K
Feb 24, 2026 Buy	Stock Option A-Award	Sullivan Gregory M Chief Medical Officer	Officer	39 012 Value: $557.5K
Dec 31, 2025 Buy	Common Stock J-Other	Saenger Bradley Chief Financial Officer	C-Suite Officer	0 Value: $0
Aug 21, 2025 Buy	Common Stock, par value $0.001 P-Purchase	Taylor Carolyn E. Director	Director	418 Value: $15.1K
Aug 21, 2025 Buy	Common Stock, par value $0.001 P-Purchase	Taylor Carolyn E. Director	Director	418 Value: $15.1K
Aug 20, 2025 Buy	Common Stock, par value $0.001 P-Purchase	Treco James Director	Director	250 Value: $9K
Aug 20, 2025 Buy	Common Stock, par value $0.001 P-Purchase	Treco James Director	Director	250 Value: $9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT TONIX PHARMACEUTICALS HOLDING CORP.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, auto...

Read Full Profile Here